Biocon Launches Affordable Bone Therapy Biosimilars

  Published 10 months ago

Biocon launches Bosanya and Aukelso biosimilars, expanding affordable osteoporosis and cancer bone therapies for patients.

  • Bosanya (60 mg/mL) treats postmenopausal osteoporosis, glucocorticoid‑induced loss; Aukelso (120 mg) prevents skeletal events in multiple myeloma
  • Both products received provisional interchangeability, allowing pharmacy‑level substitution under state regulations for greater patient access
  • Denosumab US sales hit $5 billion in 2024; Biocon aims to provide cheaper alternatives for patients

You might like these

Tata Consumer Q1 Profit Rises 15%

Reckitt Beats Q2 Sales Estimates

India's Trade Deficit Narrows in May 2025

Sobha Slips Despite Q1 Profit Rise

Polycab Q1 Profit Jumps 50%

Oberoi Realty Q2 FY26 Profit Surge

Adani Wilmar Q1 Profit Falls 25%

News that matters the most ⚡